modelLamivudineAndAbacavir
Extends from Pharmacolibrary.Drugs.ATC.J.J05AR02.
Information
| name: | LamivudineAndAbacavir | |
| ATC code: | J05AR02 | route: | oral |
| compartments: | 1 | |
| dosage: | 600 | mg |
| volume of distribution: | 1.09 | L |
| clearance: | 0.8 | L/h/kg |
| other parameters in model implementation | ||
Lamivudine and abacavir is a fixed-dose combination antiviral medication used in the treatment of HIV infection. Both drugs are nucleoside reverse transcriptase inhibitors (NRTIs) that inhibit viral replication by acting as chain terminators during reverse transcription. The combination is widely approved and recommended as part of antiretroviral therapy (ART) for adults, adolescents, and children with HIV.
Pharmacokinetics
Pharmacokinetic parameters reported for healthy adult HIV-negative volunteers; fixed-dose combination tablet administered orally.
References
Bouazza, N, et al., & Urien, S (2015). Lopinavir/ritonavir plus lamivudine and abacavir or zidovudine dose ratios for paediatric fixed-dose combinations. Antiviral therapy 20(2) 225–233. DOI:10.3851/IMP2876 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25279808
Bouazza, N, et al., & Urien, S (2017). Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patients. The Journal of antimicrobial chemotherapy 72(2) 490–495. DOI:10.1093/jac/dkw444 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27798221
Kasirye, P, et al., & Walker, AS (2012). Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1. Clinical pharmacology and therapeutics 91(2) 272–280. DOI:10.1038/clpt.2011.225 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22190066
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)